DK3027196T3 - Polysaccharid til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald - Google Patents
Polysaccharid til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald Download PDFInfo
- Publication number
- DK3027196T3 DK3027196T3 DK14745106.6T DK14745106T DK3027196T3 DK 3027196 T3 DK3027196 T3 DK 3027196T3 DK 14745106 T DK14745106 T DK 14745106T DK 3027196 T3 DK3027196 T3 DK 3027196T3
- Authority
- DK
- Denmark
- Prior art keywords
- polysaccharide
- cancer
- alpha
- hes
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Claims (15)
1. Polysaccharid, der omfatter eventuelt substituerede monosaccharid-enheder, der er koblet via alfa-glycosidbindinger, hvor polysaccharidet er et neutralt, uladet polysaccharid med en rygradskæde, der består af alfa-1,4-glycosidbundne anhydroglucose-enheder, som terapeutisk aktiv forbindelse til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald ved administration i et legemshulrum hos et individ, der er ramt af cancer.
2. Polysaccharid til anvendelse ifølge krav 1, hvor polysaccharidet er til postoperativ administration, til intraoperativ administration og/eller til præoperativ administration.
3. Polysaccharid til anvendelse ifølge krav 1 eller 2, hvor polysaccharidet omfatter glycosidbundne anhydroglucose-enheder, fortrinsvis omfatter alfa-1,4-glycosidbundne anhydroglucose-enheder og alfa-1,6-glycosidbundne anhydroglucose-enheder, hvor anhydroglucose-enhederne eventuelt er substitueret.
4. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor mindst 90 % af glycosidbindingerne i polysaccharidet er alfa-1,4-glycosidbindinger og/eller alfa-1,6-glycosidbindinger.
5. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor polysaccharidet yderligere omfatter mindst én hydroxyalkylgruppe.
6. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor polysaccharidet er hydroxyalkylstivelse, fortrinsvis hydroxethylstivelse.
7. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor canceren danner en solid tumor.
8. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor canceren er ovariecancer, ovariekarcinom, ventikelcancer, lungecancer, pancreascancer, blærecancer, levercancer, kolorektal cancer eller brystcancer.
9. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor polysaccharidet er indeholdt i en farmaceutisk acceptabel opløsning, fortrinsvis en vandig opløsning.
10. Polysaccharid til anvendelse ifølge krav 9, hvor koncentrationen af polysaccharidet i den farmaceutisk acceptable opløsning er 1 % (vægt/volumen) til 25 % (vægt/volumen), fortrinsvis 2 % (vægt/volumen) til 15 % (vægt/volumen), mere fortrinsvis 3 % (vægt/volumen) til 12,5 % (vægt/volumen) og mest fortrinsvis 4 % (vægt/volumen) til 10 % (vægt/volumen) .
11. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 eller 10, som forebygger metastase og/eller tilbagefald i et legemshulrum hos et individ, fortrinsvis bughulen.
12. Polysaccharid til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor polysaccharidet har en gennemsnitlig molekylvægt på 5 til 1200 kDa, fortrinsvis 13 til 800 kDa.
13. Polysaccharid til anvendelse ifølge krav 5 eller 6, hvor polysaccharidet har en molær substitutions (MS)-værdi i intervallet fra 0,1 til 3.
14. Sammensætning, fortrinsvis en farmaceutisk sammensætning til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald ved administration til et legemshulrum hos et individ, der er ramt af cancer, som omfatter et terapeutisk aktivt polysaccharid, der omfatter eventuelt substituerede monosaccharid-enheder, der er koblet via alfa- glycosidbindinger, hvor polysaccharidet er et neutralt, uladet polysaccharid og har en rygradskæde, der består af alfa-1,4-glycosidbundne anhydroglucose-enheder.
15. Sammensætning til anvendelse ifølge krav 14, hvor sammensætningen omfatter et polysaccharid som den eneste bestanddel, der forebygger metastasedannelse og/eller tilbagefald.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13178566.9A EP2832360A1 (en) | 2013-07-30 | 2013-07-30 | Polysaccharide for use in preventing metastasis formation and/or relapse |
| PCT/EP2014/065990 WO2015014730A1 (en) | 2013-07-30 | 2014-07-25 | Polysaccharide for use in preventing metastasis formation and/or relapse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3027196T3 true DK3027196T3 (da) | 2017-06-26 |
Family
ID=48900829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14745106.6T DK3027196T3 (da) | 2013-07-30 | 2014-07-25 | Polysaccharid til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160175340A1 (da) |
| EP (3) | EP2832360A1 (da) |
| KR (2) | KR20160044493A (da) |
| CN (1) | CN105555280A (da) |
| AU (1) | AU2014298637B2 (da) |
| CA (1) | CA2918180A1 (da) |
| DK (1) | DK3027196T3 (da) |
| ES (1) | ES2628207T3 (da) |
| HK (2) | HK1206643A1 (da) |
| HR (1) | HRP20170877T1 (da) |
| HU (1) | HUE032564T2 (da) |
| LT (1) | LT3027196T (da) |
| MX (1) | MX348932B (da) |
| PL (1) | PL3027196T3 (da) |
| PT (1) | PT3027196T (da) |
| RS (1) | RS56062B1 (da) |
| SI (1) | SI3027196T1 (da) |
| WO (1) | WO2015014730A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647096B (zh) * | 2020-05-20 | 2021-04-06 | 昆明理工大学 | 一种中性玛咖多糖及其提取方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5616765B2 (da) | 1975-02-05 | 1981-04-18 | ||
| DE4023788A1 (de) | 1990-07-26 | 1992-01-30 | Schumann Klaus | Verwendung einer waessrigen loesung einer poly-(o-hydroxyalkyl)-staerke |
| US5807833A (en) | 1995-06-07 | 1998-09-15 | University Of Southern California | Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device |
| US6207654B1 (en) | 1996-05-03 | 2001-03-27 | Bashir Zikria | Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2 |
| CN100363054C (zh) | 2002-09-04 | 2008-01-23 | 生物聚合物工程有限公司 | 全葡聚糖颗粒在抗癌药物中的应用 |
| EP1984004A4 (en) | 2006-01-17 | 2010-03-03 | Sloan Kettering Inst Cancer | THE THERAPY REINFORCING GLUCAN |
| WO2010096466A2 (en) * | 2009-02-17 | 2010-08-26 | Novelmed Therapeutics, Inc. | Methods and compositions for inhibiting cellular proliferation and surgical adhesion |
| US20130178437A1 (en) | 2010-07-09 | 2013-07-11 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| EP2809329B1 (en) * | 2012-01-30 | 2018-08-01 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch in combination with cytostatica for the treatment of cancers by reduction of tumor growth rates |
-
2013
- 2013-07-30 EP EP13178566.9A patent/EP2832360A1/en not_active Withdrawn
-
2014
- 2014-07-25 PT PT147451066T patent/PT3027196T/pt unknown
- 2014-07-25 HU HUE14745106A patent/HUE032564T2/en unknown
- 2014-07-25 KR KR1020167005343A patent/KR20160044493A/ko active Application Filing
- 2014-07-25 PL PL14745106T patent/PL3027196T3/pl unknown
- 2014-07-25 LT LTEP14745106.6T patent/LT3027196T/lt unknown
- 2014-07-25 RS RS20170591A patent/RS56062B1/sr unknown
- 2014-07-25 CN CN201480043108.7A patent/CN105555280A/zh active Pending
- 2014-07-25 KR KR1020197022364A patent/KR20190092615A/ko not_active Application Discontinuation
- 2014-07-25 SI SI201430248A patent/SI3027196T1/sl unknown
- 2014-07-25 DK DK14745106.6T patent/DK3027196T3/da active
- 2014-07-25 CA CA2918180A patent/CA2918180A1/en not_active Abandoned
- 2014-07-25 EP EP14745106.6A patent/EP3027196B1/en active Active
- 2014-07-25 WO PCT/EP2014/065990 patent/WO2015014730A1/en active Application Filing
- 2014-07-25 MX MX2016001259A patent/MX348932B/es active IP Right Grant
- 2014-07-25 AU AU2014298637A patent/AU2014298637B2/en not_active Ceased
- 2014-07-25 EP EP17160891.2A patent/EP3202408A3/en not_active Withdrawn
- 2014-07-25 ES ES14745106.6T patent/ES2628207T3/es active Active
- 2014-07-25 US US14/909,300 patent/US20160175340A1/en not_active Abandoned
-
2015
- 2015-08-03 HK HK15107429.9A patent/HK1206643A1/xx unknown
-
2016
- 2016-12-06 HK HK16113882A patent/HK1225615B/zh not_active IP Right Cessation
-
2017
- 2017-06-08 HR HRP20170877TT patent/HRP20170877T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3027196B1 (en) | 2017-03-15 |
| PT3027196T (pt) | 2017-06-26 |
| HK1225615B (zh) | 2017-09-15 |
| RS56062B1 (sr) | 2017-10-31 |
| EP3202408A2 (en) | 2017-08-09 |
| EP3202408A3 (en) | 2017-09-20 |
| KR20190092615A (ko) | 2019-08-07 |
| PL3027196T3 (pl) | 2017-09-29 |
| KR20160044493A (ko) | 2016-04-25 |
| EP2832360A1 (en) | 2015-02-04 |
| WO2015014730A4 (en) | 2015-04-09 |
| CN105555280A (zh) | 2016-05-04 |
| MX348932B (es) | 2017-07-04 |
| CA2918180A1 (en) | 2015-02-05 |
| HK1206643A1 (en) | 2016-01-15 |
| WO2015014730A1 (en) | 2015-02-05 |
| HRP20170877T1 (hr) | 2017-09-22 |
| LT3027196T (lt) | 2017-06-26 |
| MX2016001259A (es) | 2016-07-21 |
| AU2014298637A1 (en) | 2016-02-25 |
| US20160175340A1 (en) | 2016-06-23 |
| ES2628207T3 (es) | 2017-08-02 |
| EP3027196A1 (en) | 2016-06-08 |
| AU2014298637B2 (en) | 2019-03-21 |
| SI3027196T1 (sl) | 2017-07-31 |
| HUE032564T2 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525306A (ja) | 前駆細胞動員を伴う疾患の治療および予防のための多糖組成物および使用方法 | |
| DK3027196T3 (da) | Polysaccharid til anvendelse til forebyggelse af metastasedannelse og/eller tilbagefald | |
| US20160082036A1 (en) | Hydroxyalkyl starch for the treatment of cancers by reduction of tumor growth rates | |
| EP3250193B1 (en) | Use of a mixture of modified glucose polymers for reducing tumor metastasis | |
| Michalczyk et al. | Hyaluronic Acid as a Modern Approach in Anticancer Therapy-Review |